Cancer Family
Central Nervous System Embryonal Tumor
CI-CAN-00000115Explore in graph →
72 active trials18 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000115Explore in graph →
Clinical trials
240 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (32)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00407433 | Clinical Studies of Gemcitabine-Oxaliplatin | completed | Phase 2 | 156 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT01326104 | Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor(Re-MATCH) | completed | Phase 2 | 26 | University of FloridaOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT03213678 | Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 2 | Apr 21, 2026 | clinicaltrials |
| NCT03213665 | Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 2 | Apr 13, 2026 | clinicaltrials |
| NCT03526250 | Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 2 | Apr 3, 2026 | clinicaltrials |
| NCT02601950 | A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma | completed | Phase 2 | 267 | Epizyme, Inc.INDUSTRY | 9 | Jun 22, 2025 | clinicaltrials |
| NCT03233204 | Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 2 | Dec 11, 2024 | clinicaltrials |
| NCT00601003 | Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma | completed | Phase 2 | 112 | Giselle ShollerOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT03257631 | A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors | completed | Phase 2 | 53 | CelgeneINDUSTRY | 5 | Apr 16, 2024 | clinicaltrials |
| NCT02095132 | Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 76 | National Cancer Institute (NCI)NIH | 2 | Sep 26, 2023 | clinicaltrials |
| NCT03273712 | Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC) | completed | Phase 2 | 39 | University of IowaOTHER | 1 | Feb 9, 2023 | clinicaltrials |
| NCT02017964 | Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-metastatic Desmoplastic Medulloblastoma | completed | Phase 2 | 26 | Children's Oncology GroupNETWORK | 4 | Jan 9, 2023 | clinicaltrials |
| NCT01542736 | Concurrent Carboplatin and Reduced Dose Craniospinal Radiation for Medulloblastoma and Primitive Neuroectodermal Tumor (PNET) | completed | Phase 2 | 8 | University of Colorado, DenverOTHER | 1 | Jan 11, 2022 | clinicaltrials |
| NCT01869725 | Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT | completed | Phase 2 | 68 | Sue O'DorisioOTHER | 1 | Sep 22, 2021 | clinicaltrials |
| NCT02596828 | Prospective Pilot Trial to Assess a Multimodal Molecular Targeted Therapy in Children, Adolescent and Young Adults With Relapsed or Refractory High-grade Pineoblastoma | completed | Phase 2 | 4 | University of RegensburgOTHER | 1 | Aug 5, 2021 | clinicaltrials |
| NCT01619865 | Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors(GA-68) | completed | Phase 1 / Phase 2 | 223 | Sue O'DorisioOTHER | 1 | Jul 27, 2021 | clinicaltrials |
| NCT01217437 | Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors | completed | Phase 2 | 108 | National Cancer Institute (NCI)NIH | 5 | Jul 23, 2021 | clinicaltrials |
| NCT02441062 | Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors | completed | Phase 2 | 122 | Sue O'DorisioOTHER | 1 | Dec 21, 2020 | clinicaltrials |
| NCT00179803 | Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors | completed | Phase 2 | 24 | Ann & Robert H Lurie Children's Hospital of ChicagoOTHER | 1 | Aug 5, 2020 | clinicaltrials |
| NCT01614132 | Multicenter Pilot-study for the Therapy of Medulloblastoma of Adults(NOA-07) | completed | Phase 1 / Phase 2 | 33 | University of RegensburgOTHER | 1 | Mar 31, 2020 | clinicaltrials |
| NCT01977677 | Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma | completed | Phase 1 / Phase 2 | 30 | Lawrence RechtOTHER | 1 | Oct 23, 2018 | clinicaltrials |
| NCT00749723 | Therapy Optimization Trial for the Treatment of Relapsed or Refractory Brain Tumors in Children(HIT-REZ-2005) | completed | Phase 2 / Phase 3 | 174 | University Hospital, BonnOTHER | 1 | Jul 20, 2018 | clinicaltrials |
| NCT00381797 | Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma | completed | Phase 2 | 97 | National Cancer Institute (NCI)NIH | 1 | Nov 28, 2017 | clinicaltrials |
| NCT00003460 | Antineoplaston Therapy in Treating Children With Primitive Neuroectodermal Tumors(PNET) | completed | Phase 2 | 13 | Burzynski Research InstituteOTHER | 1 | Aug 24, 2017 | clinicaltrials |
| NCT01708174 | A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB) | completed | Phase 2 | 22 | Novartis PharmaceuticalsINDUSTRY | 13 | Aug 11, 2017 | clinicaltrials |
| NCT01125800 | A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB | completed | Phase 1 / Phase 2 | 76 | Novartis PharmaceuticalsINDUSTRY | 6 | Mar 20, 2017 | clinicaltrials |
| NCT00939484 | Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma | completed | Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Feb 25, 2016 | clinicaltrials |
| NCT01239316 | Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Jan 14, 2016 | clinicaltrials |
| NCT00095940 | Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors | completed | Phase 1 / Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | May 23, 2014 | clinicaltrials |
| NCT00070525 | Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma | completed | Phase 2 | 90 | National Cancer Institute (NCI)NIH | 1 | Oct 8, 2013 | clinicaltrials |
| NCT00004078 | Irinotecan in Treating Children With Refractory Solid Tumors | completed | Phase 2 | 181 | Children's Oncology GroupNETWORK | 1 | Jun 14, 2013 | clinicaltrials |
| NCT00005811 | Topotecan Hydrochloride in Treating Children With Meningeal Cancer That Has Not Responded to Previous Treatment | completed | Phase 2 | 77 | National Cancer Institute (NCI)NIH | 1 | Feb 21, 2013 | clinicaltrials |
| NCT00404495 | Combination of Irinotecan and Temozolomide in Children With Brain Tumors. | completed | Phase 2 | 83 | PfizerINDUSTRY | 8 | Apr 18, 2012 | clinicaltrials |
| NCT00520936 | A Study of Pemetrexed in Children With Recurrent Cancer | completed | Phase 2 | 72 | Eli Lilly and CompanyINDUSTRY | 1 | Feb 25, 2011 | clinicaltrials |
Data updated 22 days agoSource updated Aug 17, 2026source: clinicaltrials